COVID-19 disease increases interleukin (IL)-1β release. Anti-IL-1-treatment is effective in IL-1-mediated autoinflammatory diseases (AID). This case series presents COVID-19 in patients with IL-1-mediated and unclassified AID with immunosuppressive therapy (IT). Patient 1 is a 34-year-old woman with an unclassified AID and methotrexate. Patients 2 and 3 (14-year-old girl and 12-year-old boy, respectively) have a Cryopyrin-Associated Periodic Syndrome ( NLRP3 p.Q703K heterozygous, CAPS) treated with canakinumab 150 mg/month since three and five years, respectively. Patient 4 is a 15-year-old girl who has had familial Mediterranean fever ( MEFV p. M694V homozygous) for 3 years treated with canakinumab 150 mg/month and colchicine. All patients had a mild acute COVID-19 course, particularly the adolescent patients. A few weeks after COVID-19 recovery, both CAPS patients developed increased AID activity, necessitating anti-IL-1-treatment intensification in one patient. At day 100, one out of four patients (25%) showed positive antibody response to SARS-CoV-2. This is one of the first reports providing follow-up data about COVID-19 in AID. The risk for severe acute COVID-19 disease was mild/moderate, but increased AID activity post-COVID-19 was detected. Follow-up data and data combination are needed to expand understanding of COVID-19 and SARS-CoV-2 immunity in AID and the role of IT.
【저자키워드】 coronavirus, interleukin-1, SARS-CoV-2 antibody response, Autoinflammatory diseases, CAPS, FMF, 【초록키워드】 COVID-19, SARS-CoV-2, therapy, risk, SARS-CoV-2 immunity, COVID-19 disease, Patient, Mild, Colchicine, Follow-up, methotrexate, disease, patients, autoinflammatory disease, NLRP3, Combination, immunosuppressive, acute COVID-19, homozygous, heterozygous, positive antibody response, FIVE, effective, Mediterranean fever, Course, case sery, treated, increase, expand, COVID-19 in patient, MEFV, Periodic, 【제목키워드】 COVID-19,